167 lines
10 KiB
HTML
167 lines
10 KiB
HTML
<!DOCTYPE html>
|
|
<html lang="en">
|
|
<head>
|
|
<meta charset="UTF-8">
|
|
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
|
<title>SAFE Agreement — Preview</title>
|
|
<style>
|
|
:root {
|
|
--theme-primary: #1e3a5f;
|
|
--theme-accent: #2563eb;
|
|
--theme-secondary: #475569;
|
|
--theme-bg: #ffffff;
|
|
--theme-surface: #f8fafc;
|
|
--theme-border: #e2e8f0;
|
|
--theme-text: #1a1a1a;
|
|
--theme-text-muted: #6b7280;
|
|
--theme-heading: #111827;
|
|
--theme-font: 'Helvetica Neue', Arial, sans-serif;
|
|
}
|
|
|
|
@page { size: A4; margin: 20mm; }
|
|
* { box-sizing: border-box; margin: 0; padding: 0; }
|
|
body { font-family: var(--theme-font); font-size: 10pt; color: var(--theme-text); background: var(--theme-bg); line-height: 1.4; }
|
|
.document { max-width: 170mm; margin: 0 auto; }
|
|
.top-bar { height: 3pt; background: var(--theme-accent); margin-bottom: 10pt; }
|
|
.doc-header { text-align: center; margin-bottom: 8pt; }
|
|
.doc-title { font-size: 16pt; font-weight: 700; color: var(--theme-primary); text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 3pt; }
|
|
.doc-subtitle { font-size: 9pt; color: var(--theme-text-muted); }
|
|
hr { border: none; border-top: 0.5pt solid var(--theme-border); margin: 6pt 0; }
|
|
.meta-grid { display: grid; grid-template-columns: 120pt auto; row-gap: 2pt; margin-bottom: 8pt; }
|
|
.meta-label { font-weight: 600; color: var(--theme-text-muted); font-size: 8.5pt; }
|
|
.meta-value { font-size: 8.5pt; color: var(--theme-text); }
|
|
.section-heading { font-size: 10pt; font-weight: 700; color: var(--theme-primary); border-bottom: 1pt solid var(--theme-accent); padding-bottom: 2pt; margin: 10pt 0 6pt; text-transform: uppercase; letter-spacing: 0.5px; }
|
|
.parties-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 10pt; margin-bottom: 8pt; }
|
|
.party-label { font-size: 8pt; font-weight: 700; text-transform: uppercase; letter-spacing: 0.5px; color: var(--theme-accent); margin-bottom: 3pt; }
|
|
.party-name { font-size: 9.5pt; font-weight: 600; color: var(--theme-heading); margin-bottom: 2pt; }
|
|
.party-detail { font-size: 8pt; color: var(--theme-text-muted); line-height: 1.5; }
|
|
.terms-box { background: var(--theme-surface); border: 0.5pt solid var(--theme-border); border-left: 3pt solid var(--theme-accent); padding: 8pt 10pt; margin-bottom: 8pt; }
|
|
.terms-box-title { font-size: 8pt; font-weight: 700; text-transform: uppercase; letter-spacing: 0.5px; color: var(--theme-accent); margin-bottom: 6pt; }
|
|
.terms-kv { display: grid; grid-template-columns: 120pt auto; row-gap: 3pt; }
|
|
.terms-kv-label { font-size: 8.5pt; font-weight: 600; color: var(--theme-text-muted); }
|
|
.terms-kv-value { font-size: 8.5pt; font-weight: 700; color: var(--theme-heading); }
|
|
.legal-section { margin-bottom: 8pt; page-break-inside: avoid; }
|
|
.legal-section-heading { font-size: 9.5pt; font-weight: 700; color: var(--theme-heading); margin-bottom: 3pt; }
|
|
.legal-section-body { font-size: 9pt; line-height: 1.6; color: var(--theme-text); }
|
|
.sig-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 20pt; margin-top: 16pt; }
|
|
.sig-col { font-size: 8.5pt; }
|
|
.sig-party-label { font-size: 8pt; font-weight: 700; text-transform: uppercase; letter-spacing: 0.5px; color: var(--theme-accent); margin-bottom: 20pt; }
|
|
.sig-line { border-bottom: 0.75pt solid var(--theme-text); margin-bottom: 3pt; height: 14pt; }
|
|
.sig-field-label { font-size: 7.5pt; color: var(--theme-text-muted); margin-bottom: 10pt; }
|
|
@media print { body { -webkit-print-color-adjust: exact; print-color-adjust: exact; } .legal-section { page-break-inside: avoid; } }
|
|
</style>
|
|
</head>
|
|
<body>
|
|
<div class="document">
|
|
|
|
<div class="top-bar"></div>
|
|
|
|
<div class="doc-header">
|
|
<div class="doc-title">SAFE Agreement</div>
|
|
<div class="doc-subtitle">Simple Agreement for Future Equity</div>
|
|
</div>
|
|
|
|
<hr>
|
|
|
|
<div class="meta-grid">
|
|
<span class="meta-label">Reference:</span> <span class="meta-value">SAFE-2026-003</span>
|
|
<span class="meta-label">Effective Date:</span> <span class="meta-value">15 February 2026</span>
|
|
<span class="meta-label">Governing Law:</span> <span class="meta-value">England and Wales</span>
|
|
<span class="meta-label">Classification:</span> <span class="meta-value">Confidential</span>
|
|
</div>
|
|
|
|
<hr>
|
|
|
|
<div class="section-heading">Parties</div>
|
|
<div class="parties-grid">
|
|
<div>
|
|
<div class="party-label">Company</div>
|
|
<div class="party-name">Helix Biotech Ltd</div>
|
|
<div class="party-detail">72 Science Park Road, Cambridge, CB4 0DW, United Kingdom</div>
|
|
</div>
|
|
<div>
|
|
<div class="party-label">Investor</div>
|
|
<div class="party-name">Beacon Ventures Fund II LP</div>
|
|
<div class="party-detail">8 St James's Square, London, SW1Y 4JU, United Kingdom</div>
|
|
</div>
|
|
</div>
|
|
|
|
<div class="terms-box">
|
|
<div class="terms-box-title">Key Financial Terms</div>
|
|
<div class="terms-kv">
|
|
<span class="terms-kv-label">Purchase Amount:</span> <span class="terms-kv-value">£500,000</span>
|
|
<span class="terms-kv-label">Valuation Cap:</span> <span class="terms-kv-value">£8,000,000 post-money</span>
|
|
<span class="terms-kv-label">Discount Rate:</span> <span class="terms-kv-value">20%</span>
|
|
</div>
|
|
</div>
|
|
|
|
<div class="section-heading">Agreement</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">1. Purchase Amount</div>
|
|
<div class="legal-section-body">In consideration of the rights described in this Agreement, the Investor agrees to invest £500,000 in the Company (the "Purchase Amount"). The Company shall use the Purchase Amount for general corporate and operating purposes, including research and development activities.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">2. Valuation Cap</div>
|
|
<div class="legal-section-body">This SAFE is subject to a valuation cap of £8,000,000 post-money (the "Valuation Cap"). The Valuation Cap is used to determine the number of shares issued to the Investor upon conversion of this SAFE. The Investor will receive shares based on whichever calculation results in a lower price per share: the Valuation Cap price or the discounted price.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">3. Discount Rate</div>
|
|
<div class="legal-section-body">This SAFE includes a discount rate of 20% applicable upon conversion. This discount shall be applied to the price per share paid by new investors in the relevant equity financing round. The Investor shall receive shares at the lower of: (a) the price per share multiplied by 80%; or (b) the price per share calculated using the Valuation Cap.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">4. Most Favoured Nation</div>
|
|
<div class="legal-section-body">If the Company issues any SAFEs or convertible instruments to future investors on terms more favourable than those set out herein (including a lower valuation cap or higher discount rate), the Company shall promptly notify the Investor and the Investor shall have the right, within thirty (30) days of such notification, to elect to have this SAFE amended to incorporate such more favourable terms.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">5. Conversion Events</div>
|
|
<div class="legal-section-body">This SAFE will automatically convert into shares of the Company's preferred stock (or equivalent) upon the occurrence of any of the following events ("Conversion Events"):
|
|
|
|
(a) Equity Financing: An equity financing in which the Company sells preferred shares for aggregate gross proceeds of at least £2,000,000, at which time this SAFE converts into shares of the same class at the conversion price determined under Sections 2 and 3 above.
|
|
|
|
(b) Liquidity Event: A change of control, sale, merger, or similar transaction, at which time the Investor shall receive, at the Investor's election, either: (i) a cash payment equal to the Purchase Amount; or (ii) shares of the Company immediately prior to the liquidity event at the conversion price.
|
|
|
|
(c) Dissolution Event: In the event of a winding-up or dissolution of the Company, the Investor shall be entitled to receive, prior to any distribution to ordinary shareholders, an amount equal to the Purchase Amount, subject to the rights of any senior creditors.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">6. Termination</div>
|
|
<div class="legal-section-body">This SAFE will terminate (without any payment to the Investor) upon: (a) conversion in full pursuant to Section 5; or (b) payment in full of the Purchase Amount in the case of a dissolution event or liquidity event as described in Section 5. No party may unilaterally terminate this SAFE prior to a Conversion Event.</div>
|
|
</div>
|
|
|
|
<div class="legal-section">
|
|
<div class="legal-section-heading">7. Governing Law</div>
|
|
<div class="legal-section-body">This Agreement shall be governed by and construed in accordance with the laws of England and Wales. The parties irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to resolve any dispute arising under or in connection with this Agreement.</div>
|
|
</div>
|
|
|
|
<div class="section-heading">Signatures</div>
|
|
<div class="legal-section-body">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</div>
|
|
<div class="sig-grid">
|
|
<div class="sig-col">
|
|
<div class="sig-party-label">For the Company</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Signature</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Name / Title: Dr. Amelia Hargreaves, CEO</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Date: 15 February 2026</div>
|
|
</div>
|
|
<div class="sig-col">
|
|
<div class="sig-party-label">For the Investor</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Signature</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Name / Title: Thomas Beacon, General Partner</div>
|
|
<div class="sig-line"></div>
|
|
<div class="sig-field-label">Date: 15 February 2026</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</body>
|
|
</html>
|